Drug intelligence / Profile preview

tqf3510

Development stage: Phase 3
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Peptides
Administration: Subcutaneous

Overview

TQF3510 is a biosimilar of semaglutide developed by Chia Tai Tianqing Pharmaceutical Group. It is a synthetic peptide acting as a long-acting Glucagon-like peptide-1 (GLP-1) receptor agonist. The drug is being investigated for metabolic diseases, primarily obesity and type 2 diabetes mellitus. Mechanistically, it mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, and reducing appetite and food intake, thereby supporting weight loss and glycemic control[1][3].

Other names: semaglutide biosimilarsemaglutide injection

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on tqf3510.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tqf3510.

Explore the full profile